PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutCurrent TOCInstructions to authors
 
Gut. 1993; 34(2 Suppl): S130–S132.
PMCID: PMC1374038
Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis.
N C Tassopoulos, M G Koutelou, G Papatheodoridis, H Polychronaki, I Delladetsima, T Giannikakis, A Todoulos, A Toliopoulos, and A Hatzakis
First Department of Medicine, Western Attica General Hospital, Athens, Greece.
Abstract
To assess the safety and possible efficacy of recombinant human interferon alfa-2b in preventing the development of chronic hepatitis, 24 adults (eight men, 16 women) with acute non-A, non-B (NANB) hepatitis were recruited to a pilot study. Half of the cases were parenterally transmitted and half were community acquired. Twelve patients received 3 million units (MU) interferon three times weekly subcutaneously for six weeks and the remaining 12 patients received no treatment. Anti-hepatitis C virus (HCV) was detected in 14 (58.3%) of the 24 patients. The alanine aminotransferase activity returned to normal in nine of 12 interferon alfa-2b treated patients and six of 12 controls by week 52. Interferon alfa-2b was well tolerated, even in jaundiced patients, who only complained of mild flu like syndrome during the first week of treatment. These data are consistent with the hypothesis that interferon alfa-2b may help prevent progression to chronic hepatitis (interferon alfa-2b 25% v controls 50%), particularly in anti-HCV negative cases (interferon alfa-2b none of six v controls two of four). A randomised, double blind placebo-controlled trial is required, however, to substantiate these results further.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (534K), or click on a page image below to browse page by page.
Articles from Gut are provided here courtesy of
BMJ Group